Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 313

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 313
---
845 shares of Common Stock, valued at $2,864,074. |

| 3. | Each                                                                                                                            
 holder of Predecessor’s common stock received a pro rata portion of up to 12,000 earnout shares of restricted Common Stock (the 
 “BCA Earnout Shares”), valued at $5,880,000, 10,000 of which are subject to vesting upon the achievement of certain stock       
 price-based earnout targets and 2,000 of which are subject to vesting upon a change of control, respectively.                   |

| 4. | Certain                                                                                                                      
 holders of Predecessor’s common stock received a pro rata portion of 8,750 earnout shares of Common Stock (the “Reallocation 
 Shares”), valued at $4.29 million, which became fully vested upon the Closing.                                               |

| 5. | Certain                                                                                                                               
 holders of Predecessor’s common stock and convertible bridge notes received a pro rata portion of 10,000 earnout shares (the “IND     
 Earnout shares”) of restricted Common Stock, valued at $4,900,000, which vested when the Company filed an investigational new drug    
 (“IND”) application with the Food and Drug Administration (“FDA”). The earning of these shares was accompanied                        
 by a forfeiture of 10,000 restricted shares of Common Stock held by the sponsor following receipt of an acknowledgement notice by the 
 Sponsor.                                                                                                                              |

| 6. | Each                                                                                                                                            
 outstanding Predecessor option was converted into an option to purchase a number of shares of Common Stock, equal to the Predecessor’s          
 common stock underlying the option multiplied by the Exchange Ratio factor of 0.064452, at an exercise price per share equal to the Predecessor 
 option exercise price divided by the Exchange Ratio factor.                                                                                     |

| 7. | Each                                                                                                                                         
 warrant to purchase the Predecessor’s preferred stock was converted into a warrant to acquire a number of shares of Common Stock             
 obtained by dividing the warrant as-if-exercised liquidation preference by $1,000.00, with the exercise price equal to the total Predecessor 
 warrant exercise amount divided by the number of shares of Common Stock issuable upon exercise.                                              |

| 8. | The                                                                                                                         
 Predecessor’s bridge notes automatically converted into shares of the Company’s Series A Preferred Stock, par value $0.0001 
 per share (the “Series A Preferred Stock”), at a